Acesso livre
Acesso livre

Infectologia

Estudo de coorte | Vacinação contra COVID-19 durante o início da gestação não foi associada com risco aumentado de anomalias fetais congênitas.

27 Abr, 2022 | 15:42h

Association of COVID-19 Vaccination During Early Pregnancy With Risk of Congenital Fetal Anomalies – JAMA Pediatrics

Comentários:

COVID vaccine in early pregnancy not tied to birth defects – CIDRAP

No Sign That COVID Vaccine in Pregnancy Raises Birth Defect Risk – HealthDay

Reinfecções por SARS-CoV-2: visão geral da eficácia e duração da imunidade natural e híbrida.

27 Abr, 2022 | 15:40h

SARS-CoV-2 reinfections: Overview of efficacy and duration of natural and hybrid immunity – Environmental Research

Estudos relacionados: Rates of COVID-19 Among Unvaccinated Adults With Prior COVID-19 – JAMA Network Open E Comentários: COVID-19 infection granted patients strong and long-lasting protection from reinfection – Providence Health & Services E COVID-19 infection may offer similar immunity as vaccination – CIDRAP

Revisão sistemática | Desempenho de sensores portáteis na detecção de infecção por SARS-CoV-2.

27 Abr, 2022 | 15:38h

The performance of wearable sensors in the detection of SARS-CoV-2 infection: a systematic review – The Lancet Digital Health

 

Comentário no Twitter

Sob licença de (CC BY 4.0)

OMS recomenda o nirmatrelvir-ritonavir para o tratamento da COVID-19 e pede para uma maior distribuição geográfica.

25 Abr, 2022 | 12:47h

WHO recommends highly successful COVID-19 therapy and calls for wide geographical distribution and transparency from originator – World Health Organization

Ver também:

A living WHO guideline on drugs for covid-19 – The BMJ

Therapeutics and COVID-19: living guideline – World Health Organization

Conteúdos relacionados:

Oral Nirmatrelvir for High-Risk, Nonhospitalized Adults with Covid-19 – New England Journal of Medicine

Prescribing Nirmatrelvir–Ritonavir: How to Recognize and Manage Drug–Drug Interactions – Annals of Internal Medicine

The COVID-19 Treatment Guidelines Panel’s Statement on Potential Drug-Drug Interactions Between Ritonavir-Boosted Nirmatrelvir (Paxlovid) and Concomitant Medications – NIH COVID-19 Treatment Guidelines Panel

 

Comentário no Twitter

 

CDC alerta sobre novos casos de hepatite de origem desconhecida.

25 Abr, 2022 | 12:44h

News Release: CDC Alerts Providers to Hepatitis Cases of Unknown Origin – Centers for Disease Control and Prevention

Ver diretriz: Recommendations for Adenovirus Testing and Reporting of Children with Acute Hepatitis of Unknown Etiology – Centers for Disease Control and Prevention

Comentários:

CDC issues health advisory about acute hepatitis in children – CNN

CDC Issues Alert for Hepatitis in Children With Adenovirus Infection – WebMD

Conteúdos relacionados:

Could Mysterious Hepatitis Cases be Triggered by COVID-19? – Health Policy Watch

Increase in hepatitis (liver inflammation) cases in children under investigation – UK Health Security Agency

U.S., U.K. investigating unusual cases of hepatitis in young children – STAT

Acute hepatitis of unknown aetiology – the United Kingdom of Great Britain and Northern Ireland – World Health Organization

Increase in acute hepatitis of unknown origin among children – United Kingdom – European Centre for Disease Prevention and Control

Mysterious liver illness seen in kids in US, Europe – Associated Press

Análise longitudinal de dados de 15 países | Rigor das políticas e saúde mental durante a pandemia de COVID-19.

25 Abr, 2022 | 12:39h

Policy stringency and mental health during the COVID-19 pandemic: a longitudinal analysis of data from 15 countries – The Lancet Public Health

Comunicado de imprensa: Stricter COVID-19 measures associated with negative mental health effects and lower opinion of government’s pandemic response, new research suggests – The Lancet

Comentário: Stricter Pandemic Policies Took Toll on Mental Health — Women tended to be more affected than men – MedPage Today

Resultados de 96 semanas de estudo randomizado | Eficácia e segurança de dolutegravir ou darunavir combinados com lamivudina e adicionados a zidovudina ou tenofovir como tratamento de segunda linha para infecção pelo HIV.

25 Abr, 2022 | 12:34h

Efficacy and safety of dolutegravir or darunavir in combination with lamivudine plus either zidovudine or tenofovir for second-line treatment of HIV infection (NADIA): week 96 results from a prospective, multicentre, open-label, factorial, randomised, non-inferiority trial – The Lancet HIV

Comentário convidado: Game-changing study of second-line HIV treatment – The Lancet HIV (necessário cadastro gratuito)

Estudo original: Dolutegravir or Darunavir in Combination with Zidovudine or Tenofovir to Treat HIV – New England Journal of Medicine

 

Comentário no Twitter

 

Estudo randomizado | AZD7442 (tixagevimabe–cilgavimabe) intramuscular para prevenir Covid-19.

25 Abr, 2022 | 12:29h

Intramuscular AZD7442 (Tixagevimab–Cilgavimab) for Prevention of Covid-19 – New England Journal of Medicine

 

Comentário no Twitter

 

[Comunicado de imprensa – ainda não publicado] Novas diretrizes da OMS recomendam um tratamento mais simples e seguro para doença criptocócica em pessoas que vivem com HIV.

25 Abr, 2022 | 12:28h

New guidelines from WHO recommend a simpler, safer treatment for cryptococcal disease in people living with HIV – World Health Organization

Estudo relacionado: Single-Dose Liposomal Amphotericin B Treatment for Cryptococcal Meningitis – New England Journal of Medicine (link para o resumo – $ para o texto completo)

Vacinação contra SARS-CoV-2 e miocardite em um estudo de coorte nórdico com 23 milhões de residentes.

25 Abr, 2022 | 12:26h

SARS-CoV-2 Vaccination and Myocarditis in a Nordic Cohort Study of 23 Million Residents – JAMA Cardiology

Editorial: Communicating the Benefits of Vaccination in Light of Potential Risks

Mantenha-se atualizado em sua especialidade

 

Escolha quantas especialidades quiser.